Bicycle Therapeutics — Third Quarter 2026 Earnings Summary

Bicycle Therapeutics received FDA Orphan Drug Designation for nuzefatide pevedotin to treat pancreatic cancer while advancing its Phase 2 clinical trial for the same indication. The company plans to initiate its first company-sponsored radioligand clinical trial for BT1702 in the second half of 2027 and expects to report survival data for zelenectide pevedotin in the same period. For the third quarter ended September 30, 2026, the company reported collaboration revenue of $34.1 million and a net loss of $10.5 million. As of September 30, 2026, Bicycle Therapeutics held $469.9 million in cash and cash equivalents, providing an expected runway into 2030.